Tradestie Institutional Equity Comparison Engine
FGEN vs CRBP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FGEN Overall Edge
FGEN Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to FibroGen, Inc (FGEN) driven by superior Valuation, Momentum & Technical while CRBP counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, FGEN trades at 61.4x Forward P/E with -499.1% operating margin (+774.8% YoY revenue) versus CRBP at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, FGEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
FGEN
FGEN 61.4x vs CRBP N/M Fwd P/E
Growth & Margin Winner
CRBP
Op Margin -499.1% vs 0.0% ยท YoY +774.8% vs -100.0%
Momentum & Technical Winner
FGEN
1Y -28.8% vs -69.5% ยท 52W Pos 44% vs 6%
Options & Structure Winner
CRBP
UNCLASSIFIED (N/A IV) vs BREAKDOWN (66th %ile IV)
FGEN
NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap
$36.5M
1M Return
+16.57%
1Y Return
-28.84%
Forward P/E
61.4x
Unified AI Score
61.2 / 100
BUY
Tech 60.0
Fund 56.0
Flow 50.0
Mom 60.0
CRBP
NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap
$69.9M
1M Return
-25.33%
1Y Return
-69.51%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 43.0
Fund 54.0
Flow 69.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
FGEN -28.84%
CRBP -69.51%
Spread: +31.0 pp (FGEN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
FGEN TTM Op. Margin: -499.1%
CRBP TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs CRBP. Trailing 12-month operating profitability (FGEN -499.1% vs CRBP 0.0%) and valuation multiples (FGEN 61.4x vs CRBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FGEN | CRBP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $36.5M | $69.9M | Larger Scale | CRBP |
| Trailing P/E Ratio Valuation | 61.4x | N/M | Lower Multiple | FGEN |
| Forward P/E Ratio Valuation | 61.4x | N/M | Lower Multiple | FGEN |
| Revenue Growth (YoY) Growth | +774.8% | -100.0% | Higher Growth | FGEN |
| Operating Margin (TTM) Profitability | -499.1% | 0.0% | Higher Margin | CRBP |
| Net Profit Margin Profitability | 2598.9% | 0.0% | Higher Margin | FGEN |
| Return on Equity (ROE) Capital Efficiency | -1015.8% | -131.5% | Higher ROE | CRBP |
| 52-Week Range Position Momentum | 44% ($0โ$22) | 6% ($3โ$13) | Stronger Trend | FGEN |
| Beta / 30D Volatility Risk Regime | -20.79ฮฒ ยท 102% Vol | 1.93ฮฒ ยท 121% Vol | Lower Realized Risk | FGEN |
| Unified Institutional Score Composite Signal | 61.2 / 100 (BUY) | 45.0 / 100 (HOLD) | Higher Composite | FGEN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full FGEN vs CRBP Buy Guide
FGEN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CRBP
BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
66th %ile
IV Regime
Elevated (60thโ80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither FGEN nor CRBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.